Alzheimer's drug benefits 'too small' to offer on NHS, NICE finds
By Lee Peart 19 June 2025
The benefits from Alzheimer’s drugs donanemab and lecanemab are too small to justify the additional costs to the NHS, NICE has found.
Intensive Support Advisor
£32,061.00 to £34,434.00, Grade 7
Wakefield, West Yorkshire£32,061.00 to £34,434.00, Grade 7
Early Intervention and Prevention Practitioner
Career Grade 7 to 8
Wakefield, West YorkshireCareer Grade 7 to 8
Most Read News
- Unions slam government's suggested pay rise for healthcare professionals in 2026
- BREAKING NEWS: 'We're turning a corner', Streeting hails NHS productivity growth
- MHRA reforms will speed up path for rare therapies
- Scottish Government invests £4.8m on type 2 diabetes prevention programme
- Requires improvement rating a 'catalyst for change', says trust
Intensive Support Advisor
£32,061.00 to £34,434.00, Grade 7
Wakefield, West Yorkshire£32,061.00 to £34,434.00, Grade 7
Early Intervention and Prevention Practitioner
Career Grade 7 to 8
Wakefield, West YorkshireCareer Grade 7 to 8
Most Read News
- Unions slam government's suggested pay rise for healthcare professionals in 2026
- BREAKING NEWS: 'We're turning a corner', Streeting hails NHS productivity growth
- MHRA reforms will speed up path for rare therapies
- Scottish Government invests £4.8m on type 2 diabetes prevention programme
- Requires improvement rating a 'catalyst for change', says trust
©2024 Hemming Group Limited. Registered in England and Wales. Registered No: 490200. VAT number GB342 023 408
